SAM pointed domain containing ETS transcription factorGenealiases: PDEF · bA375E1.3
Q-omics provides the consensus-scored SPDEF profile across patient tissues and cancer cell-line models. SPDEF expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPDEF is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, SPDEF RNA expression shows 16,529 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, LUAD, and BRCA as cancer lineages where SPDEF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDEF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDEF survival associations across molecular data types. SPDEF RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDEF RNA expression–survival associations across cancer types. High SPDEF expression shows unfavorable associations in KIRC and PAAD, but favorable associations in UCEC, HNSC, BLCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPDEF RNA expression.
This table summarizes SPDEF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SPDEF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDEF shows lower tumor expression in COAD and LUSC and higher tumor expression in LUAD, UCEC, BRCA and THCA. The LUAD box plot shows higher SPDEF RNA expression in tumor versus normal tissue (log2 FC = +3.350, t-test p < 0.001).
This table shows molecular features associated with SPDEF in patient tissues and cancer cell lines. In patient samples, SPDEF shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPDEF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUAD.
